HEALTH PROFESSIONAL · SOURCE READING

Tyrosine kinase inhibitors

Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: January 6, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Childhood LCH / Recurrent, Refractory, or Progressive Childhood LCH / Treatment of recurrent, refractory, or progressive high-risk disease: multisystem LCH / Targeted therapy

Evidence (tyrosine kinase inhibitors):

Imatinib has been shown to decrease differentiation of CD34-positive stem cells to dendritic cells. Small case reports of its efficacy in patients with LCH have been published.[152,153]

Source links and citations

Publication references

Read the original reference and check its publication notices.

PubMed 19687437 · Original source
PubMed 20733125 · Original source

Preserved source evidence · Not medical advice